Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma | MicrobiomeTrials← Back to trialsNCT03647358
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2018-08-21Est. Completion: 2027-08
Enrollment target: 75 participants Locations- Memorial Sloan Kettering Cancer Center, New York, New York, United States
Other microbiome trials you might be interested in
Advanced CancerMetastatic CancerSolid TumorMelanomaNon-small Cell Lung Cancer (NSCLC)Colorectal Cancer (CRC)Anaplastic Thyroid Cancer (ATC)
This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with ad…
Los Angeles, United StatesEst. completion Apr 1, 2028
Thyroid DiseasesThyroid Cancer
Surgery
Postoperative Pain
This study aimed to evaluate the effectiveness, safety, and implementation outcomes of a WeChat mini program-supported t…
Shanghai, ChinaEst. completion Dec 31, 2028